Natural Killer Cells: Clinical Trials

11 trials of Natural Killer Cells, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 4 terminated, 1 active not recruiting, 1 unknown. 11 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 211Completed 5, Terminated 4, Active not recruiting 1, Unknown 1
Phase 14Active not recruiting 1, Completed 1, Terminated 1, Unknown 1

Follow Natural Killer Cells: new trials by email Literature Review of Natural Killer Cells trials Research Report on Natural Killer Cells

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Natural Killer Cells, Temozolomide, Irinotecan - Relapsed Neuroblastoma, Refractory Neuroblastoma
Phase 1 / Phase 2Active not recruitingNationwide Children's Hospital312022-09-012026-09-16
Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia
NK Cells + Chemotherapy Starting - Acute Myeloid Leukemia
Phase 1 / Phase 2UnknownHospital de Clinicas de Porto Alegre302017-04-012019-10-15
Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors
Allogeneic HCT, Donor NK Cell Infusion - Ewing Sarcoma, Neuroblastoma
Phase 2TerminatedMonica Thakar152013-03-202025-03-19
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
Preparative Regimen, NK Cells, Interleukin-2 - Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase 2CompletedMasonic Cancer Center, University of Minnesota252011-09-012020-05-13
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
Rituximab, Interleukin-2, Natural killer cells - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Phase 2CompletedMasonic Cancer Center, University of Minnesota162010-08-012018-02-06
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
Fludarabine, Cyclophosphamide, Cyclosporine - Ovarian Cancer, Fallopian Tube Cancer
Phase 2CompletedMasonic Cancer Center, University of Minnesota132010-07-012017-12-28
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Natural Killer Cells, Fludarabine, Cyclophosphamide - Leukemia, Myelogenous, Acute
Phase 2TerminatedMasonic Cancer Center, University of Minnesota152010-07-012017-12-28
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)
Epratuzumab, Fludarabine, Cyclophosphamide - Leukemia, Pediatric Cancer
Phase 2TerminatedM.D. Anderson Cancer Center22009-07-012014-05-22
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
aldesleukin, allogeneic natural killer cells, rituximab - Leukemia, Lymphoma
Phase 1 / Phase 2TerminatedMasonic Cancer Center, University of Minnesota62008-01-012017-12-28
Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia
aldesleukin, therapeutic allogeneic lymphocytes, cyclophosphamide - Leukemia
Phase 2CompletedMasonic Cancer Center, University of Minnesota212005-03-012017-12-28
Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
aldesleukin, natural killer cells, cyclophosphamide - Acute Myelogenous Leukemia
Phase 1 / Phase 2CompletedMasonic Cancer Center, University of Minnesota502005-01-012017-12-28

Conditions studied

Leukemia, Myeloid, Acute (5)  ·  Leukemia (3)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Neuroblastoma (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Brain Neoplasms (1)  ·  Breast Neoplasms (1)  ·  Burkitt Lymphoma (1)  ·  Central Nervous System Neoplasms (1)  ·  Congenital Abnormalities (1)  ·  Fallopian Tube Neoplasms (1)  ·  Lymphoma (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)  ·  Lymphoma, Extranodal NK-T-Cell (1)

Sponsors

Masonic Cancer Center, University of Minnesota (7)  ·  Hospital de Clinicas de Porto Alegre (1)  ·  M.D. Anderson Cancer Center (1)  ·  Monica Thakar (1)  ·  Nationwide Children's Hospital (1)

Countries

United States (10)  ·  Brazil (1)

Top investigators

Veronika Bachanova, MD (2)  ·  Anna Franklin, MD (1)  ·  Jeffrey Miller, M.D. (1)  ·  Jeffrey Miller, MD (1)  ·  Jeffrey S. Miller, M.D. (1)  ·  Lucia Silla, Doctor (1)  ·  Mark Ranalli, MD (1)  ·  Melissa Geller, MD (1)  ·  Monica Thakar, MD (1)  ·  Sarah Cooley, MD (1)

Results publications

PMID 24719405, PMID 29218366, PMID 31401903

NIH funding

P01CA065493 (1)